AMG133, a bispecific hybrid that comprises two GLP-1R agonists conjugated to a monoclonal anti-GIPR antagonist25,26 is currently in phase 2 clinical development for the treatment of obesity and type 2 diabetes. The gene discussed is GIPR; the disease is obesity disorder.